

1 Safety and efficacy of Pulmonary physiotherapy in hospitalized patients  
2 with severe COVID-19 pneumonia (PPTCOVID Study): A prospective,  
3 randomised, single-blind, controlled trial

4  
5 **Short Title:** “Safety and efficacy of Pulmonary physiotherapy in patients with severe COVID-  
6 19”

7  
8 Mohammad Javaherian<sup>1,2</sup>, Azadeh Shadmehr<sup>1</sup>, Abbasali Keshtkar<sup>3</sup>, Mohammad-Taghi Beigmohammadi<sup>4</sup>, Narges  
9 Dabbaghipour<sup>1</sup>, Aabis Syed<sup>1</sup>, Behrouz Attarbashi Moghadam<sup>1\*</sup>

10 <sup>1</sup> Department of Physiotherapy, School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran.

11 <sup>2</sup> Liver Transplantation Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical  
12 Sciences, Tehran, Iran.

13 <sup>3</sup> Department of Health Sciences Education Development, School of Public Health, Tehran University of Medical  
14 Sciences and Health Services, Tehran, Iran.

15 <sup>4</sup> Department of Anesthesiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences,  
16 Tehran, Iran.

17 \* Corresponding author

18 Email: Attarbashi@tums.ac.ir

19

## 20 **Abstract**

21 **Background:** Pulmonary physiotherapy (PPT) is an important treatment in the management of  
22 patients with different types of pulmonary disorders. We aimed to evaluate safety and efficacy of  
23 PPT in hospitalized patients with severe COVID-19 pneumonia.

24 **Methods:** In this randomised, single-blind, controlled trial, we enrolled hospitalized, non-  
25 intubated patients (18 to 75 years with oxygen saturation (Spo<sub>2</sub>) in free-air breathing  $\leq$ 90%) with  
26 COVID-19 pneumonia at a referral hospital. Participants were randomly assigned (1:1) to  
27 receive PPT (six sessions PPT with breathing exercises and airway clearance techniques) or  
28 basic care. The primary outcomes were venous blood O<sub>2</sub> (pO<sub>2</sub>) and CO<sub>2</sub> (pCO<sub>2</sub>) pressures,  
29 Spo<sub>2</sub>, and three-minute walking test (3MWT) that were assessed before and end of sixth session.  
30 Secondary outcomes included level of dyspnea, venous blood PH, one-month mortality, three-  
31 month mortality and short form-36 (SF-36) after one and three months. The assessor was blinded  
32 to the assignment. This trial is registered with ClinicalTrials.gov (NCT04357340).

33 **Findings:** In April-May 2020, 40 participants were randomly assigned to PPT or basic care  
34 groups. While at the end of intervention, pO<sub>2</sub> (adjusted mean difference to baseline measure  
35 (AMD) 6.43 mmHg [95%CI 2.8, 10.07], P<0.01), Spo<sub>2</sub> (AMD 4.43% [95%CI 2.04, 6.83],  
36 P=0.0011), and 3MTW (AMD 91.44 m [95%CI 68.88, 113.99], P<0.01) were higher in PPT  
37 group and basic care group, pCO<sub>2</sub> was not improved (AMD -2.1 mmHg [95%CI-6.36, 2.21],  
38 P=0.33). Mortality rate was 20% (OR adjusted to baseline Spo<sub>2</sub> .19 [95%CI .03, 1.30], P=.09)  
39 and 25% (OR adjusted to baseline Spo<sub>2</sub> .16 [95%CI .26, 1.05], P=.056) lower in the PPT group  
40 at three-month at one-month and three-month, respectively. There were no significant  
41 differences in most SF-36 domains scores after one and three months. No serious adverse event  
42 was observed during PPT sessions.

43 **Conclusion:** Early PPT can be considered a safe and effective therapeutic choice for patients with  
44 severe COVID-19.

45 **Keywords:** Physiotherapy, Pulmonary, Coronavirus Disease 2019, COVID-19, Rehabilitation

46

## 47 **Introduction**

48 In late December 2019, the coronavirus infection pneumonia epidemic broke out and rapidly  
49 spread worldwide [1]. Now almost all countries are challenging with coronavirus disease 2019  
50 (COVID-19). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) not only  
51 induced more than 194 million definite COVID-19 cases and four million mortality numbers yet,  
52 but it also caused a challenge in healthcare systems and the economic conditions of most  
53 countries [2].

54 Patients with COVID-19 can present influenza-like signs and symptoms like fever (89%), cough  
55 (68%), fatigue (38%), excessive pulmonary secretion (EPS) or sputum (34%), and breathlessness  
56 (19%). The disease can appear asymptomatic or mild lower respiratory tract illness through  
57 severe viral pneumonia with acute respiratory distress syndrome and even death [3]. Age > 60  
58 years, some underlying noncommunicable diseases like diabetes, hypertension, cardiovascular,  
59 kidney, and lung diseases, cerebrovascular diseases, immunosuppression, obesity, cancer, and  
60 even mental disorders are reported as risk factors associated with severe COVID-19 and  
61 mortality [3].

62 Pulmonary physiotherapy (PPT) is a comprehensive therapeutic method that is aimed to improve  
63 patient's respiratory symptoms, train effective cough, clear the airways, decrease symptoms of  
64 dyspnea, re-expansion of atelectatic lung, provide short-term improvement in lung-thorax  
65 compliance, reduce the complications related to disease, minimize disability and finally improve  
66 the health-related quality of life (HRQOL) [4-6].

67 Up to now, some studies with different designs and levels of evidence have been suggested PPT  
68 strategies for hospitalized patients with various stages of COVID-19 pneumonia [1, 4, 7-13].

69 Almost all of their recommendations are based on expert opinion origin and reported data from  
70 other viral pneumonia diseases such as influenza. These recommendations seem to have not  
71 sufficient experimental evidence in connection with COVID-19. The original studies have  
72 focused on rehabilitative or physical therapy processes after the severe stage of COVID-19 more  
73 than the acute stage to recovery muscle wasting, aerobic deconditioning, and possibly happened  
74 disability due to prolonged immobility [14].

75 Although some researchers and expert clinicians suggested that early PPT can be tailored in the  
76 condition of acute respiratory disease to prevent further muscular and aerobic systems

77 deterioration, helping the therapeutic process, decrease hospitalization duration, and facilitate  
78 future recovery in patients with COVID-19 [4, 7, 11, 12], but there are some researchers  
79 recommend that use of this treatment should be avoided for patients with COVID-19 especially  
80 in the severe or critical stage [3] except in some circumstance like the presence of a high amount  
81 of EPS [9]. Most of these researchers believe that this treatment can be unsafe and ineffective for  
82 patients with acute COVID-19. Although some researchers reported that early PPT can be safe  
83 and be associated with clinical improvement, prevention of potential complications due to  
84 underlying diseases and immobilisation, short length of stay and a decrease of mortality rate in  
85 patients with critical diseases [15-18], but there is no high-quality randomised controlled trial  
86 (RCT) evaluate the safety and efficacy of PPT in patients with severe COVID-19 after more than  
87 18 months from SARS-Cov-2 spread in the world. This study was aimed to evaluate the safety  
88 and efficacy of PPT on venous blood gas (VBG) analysis, peripheral blood oxygen saturation  
89 (Spo<sub>2</sub>), three-minute walking test (3MWT), one-month and three-month HRQOL and mortality  
90 rate in non-intubated patients with severe COVID-19 pneumonia. The result of this study can  
91 guide the clinicians and future researchers to include PPT into the protocol of severe COVID-19  
92 management or not. It was hypothesized that participants receive PPT demonstrate improvement  
93 in venous blood O<sub>2</sub> & CO<sub>2</sub> pressures (pO<sub>2</sub> and pCO<sub>2</sub>, mmHg), Spo<sub>2</sub>, 3MWT, level of dyspnea,  
94 one-month and three-month HRQOL, and decrease of one-month and three-month mortality  
95 rates than participants in the control group.

## 96 **Material and methods**

### 97 **Study design**

98 This was a single-center, single-blind, prospective, two parallel-armed RCT comparing the  
99 efficacy of six sessions PPT + basic care with basic care alone in hospitalized patients with  
100 COVID-19 pneumonia. In April and May 2020, participants were recruited at COVID-19  
101 intermediate care wards and intensive care units of Imam Khomeini Hospital Complex, Tehran,  
102 Iran. IKHC is known as the largest and one of the referral hospitals in Iran. Any related adverse  
103 events during three days were monitored and recorded by a data safety monitoring committee.  
104 Members of this committee were physicians of intermediate care wards and one medical ethics  
105 specialist. They were asked to follow the procedure of applied interventions on patients by  
106 researchers and possible occurred adverse events which may be related to PPT. This trial was

107 approved by the Ethical Committee of Tehran University of Medical Sciences  
108 (IR□TUMS.VCR.REC.1399.205). The authors had access to patients' medical records until  
109 three months after recruitment.

## 110 **Participants**

111 All participants were patients with COVID-19 pneumonia at a severe stage [3]. The inclusion  
112 criteria were individuals: 1) 18 to 75 years old; 2) with confirmed COVID-19 by positive  
113 reaction real-time polymerase chain reaction test and presence of ground-glass opacification in  
114 their chest computed tomography scan; 3) severe stage of COVID-19 pneumonia indicated by  
115  $\text{Spo}_2 < 90\%$  after two-minute breathing the free air and respiratory rate  $> 30$  breaths/min ;4) with  
116 full consciousness and oriented; 5) able to walk; 6) with  $\text{O}_2$  saturation  $< 90\%$  after; 7)  $100 \leq$   
117  $\text{PaO}_2/\text{FiO}_2 \leq 200$  mmHg, and 8) able to read and write in Persian. The exclusion criteria  
118 included 1) presence of any type of musculoskeletal disorder that prohibits the patient from  
119 participating in the study; 2) history of intubation due to COVID-19 pneumonia; and 3) Any type  
120 of obvious clinically mental or cognitive impairment. Potentially eligible participants were  
121 screened by review the admitted patient's medical records and a preliminary assessment. A  
122 signed informed consent form was obtained from all patients after explaining the study details to  
123 them.

124 Participants who met one of the following conditions were withdrawn/dropped out from the  
125 study: 1) Unable to complete at least three sessions; 2) Dissatisfaction to continue to the study  
126 for any reason; 3) Intubation or die during interventions; and; 5) Occurring unpredictable adverse  
127 events during applying interventions.

## 128 **Randomisation and masking**

129 After consent was obtained, eligible individuals were assigned (1:1) to one of the treatment  
130 groups using the blocked-balanced randomisation method [19] (block size: 4): 1) the  
131 experimental group (received six sessions PPT in addition to basic care interventions) or 2) the  
132 control group (received basic care only). Randomization was done using an online system that  
133 provides difference blocks order based on a random number (<https://www.sealedenvelope.com>).  
134 The sealed envelopes were provided and stamped based on the order of randomised groups by a  
135 researcher (BAM) who had no role in the participants' assessment and treatment.

136 Physiotherapists allocated participants based on the order of the envelopes. The assessor and  
137 statistical analysis team were masked to treatment allocation. The assessor had not also access to

138 patient's medical record. As PPT consists of some techniques that require the patient's  
139 cooperation actively; therefore, participants masking was impossible.

## 140 **Procedures**

141 The process of enrollment, recruitment and the baseline assessment was performed in a same  
142 day. Medical history and demographic data were collected from participants after recruitment.  
143 Patients underwent clinical evaluation at baseline, including VBG analysis, 3MWT, Spo2, and  
144 level of dyspnea. In order to VBG analysis, blood samples were taken from the upper extremity  
145 peripheral veins after two-minutes of breathing free air in fowler's position by a nurse. Samples  
146 were immediately analyzed [20]. At this time, the patient's Spo2 was assessed using an index  
147 finger pulse oximeter [21]. In the 3MWT, patients were asked to continue walking as their  
148 tolerance without portable oxygen receive using comfortable footwear. Heart rate and Spo2 were  
149 monitored and the test was stopped in the condition of Spo2 < 80%, patient's inability to  
150 continue, dyspnea, chest or limb pain [22]. Rated perceived exertion (RPE) during exercises was  
151 evaluated using the Borg scale immediately after 3MWT [23]. The level of dyspnea was  
152 evaluated using the visual analog scale [24]. To assess the level of dyspnea, the patient was  
153 instructed that zero stands for no breath shortness and 10 shows maximum breath shortness.  
154 Patient was asked to mark his/her feeling of dyspnea during the past 24 hours on the paper [25].  
155 The interventions were delivered over three days. The number of days and sessions for applying  
156 the intervention was determined after analyzing the mean of staying duration at intermediate care  
157 wards, where patients with severe COVID-19 were admitted. Based on the result of primary  
158 analysis, 78% of patients had admitted to intermediate care wards stayed for 3-4 days and they  
159 were then transferred to other care wards (normal care wards or intensive care units).  
160 Patients underwent a second assessment time at the end of day three (after the sixth session).  
161 Participants were also followed up to one month and three months to evaluate their survival rate  
162 (using electronic medical records) and HRQOL using telephone assessment of short form-36  
163 (SF-36) questionnaire.

## 164 **Basic care group:**

165 Participants in the basic care group received usual medical care, including medication based on  
166 the national guideline of COVID-19 [26], oxygen therapy, possibly non-invasive ventilation  
167 intervention, nursing care and monitoring, and etc. They also had one session of breathing  
168 education with 40 minutes duration includes effective cough, if they felt EPS, diaphragmatic

169 breathing, and upper chest muscles relaxation. They also received an incentive spirometer and  
170 instructions on how to use it. They also were advised to walk as tolerate, even using a portable  
171 oxygen cylinder. This educational session was held in one of three days after the first assessment  
172 and before the second assessment.

### 173 **Pulmonary physiotherapy group:**

174 In addition to basic care interventions, patients allocated to the PPT group received a totally 6  
175 PPT sessions for three consecutive days (twice daily: one session in the morning and one session  
176 in the afternoon). PPT was started at the same day that patient was recruited. Patients received  
177 two sessions of PPT in that day. Two expert pulmonary physiotherapists assessed patients  
178 immediately before every session to select the techniques based on their findings. It is reported  
179 that about 34% of patients with COVID-19 pneumonia present signs and symptoms of EPS [3].  
180 If the patient presented signs and symptoms of EPS presence like wheezing sound, and sputum  
181 production, airway clearance techniques (ACTs) were applied. These techniques included active  
182 cycle of breathing (ACBT), Autogenic Drainage, vibration, and postural drainage. If there was  
183 any contraindication for these techniques, only an effective cough technique was used. ACTs  
184 were continued until successful secretions clearance based on therapists' assessment [27]. These  
185 patients and whom without EPS signs and symptoms then received Inspiratory Hold Technique  
186 (IHT) exercises. During these exercises, patients held their breath at the end of inspiration  
187 without using a Valsalva maneuver following by a relaxed exhalation. The physiotherapists  
188 emphasized diaphragmatic breathing while performing the IHT by setting their palmar surface of  
189 hand on patients' costal margin bilaterally to facilitate abdominal wall motion. Also, patients  
190 were educated to relax their upper chest muscles during exercises [27]. This technique was  
191 performed ten times in three sets with 2 minutes rest between each set: 1) Set 1: three-second  
192 hold, six-second rest; 2) Set 2: six-second hold; 12-second rest; 3) Set 3: 10-second hold, 20-  
193 second rest. A summary of applied PPT techniques, contraindications, and criteria of holding the  
194 interventions, is presented in Fig 1.

195 **Fig 1. The protocol of applied pulmonary physiotherapy to patients with or without excessive pulmonary**  
196 **secretion.**

197 Also, patients in this group underwent mild aerobic exercise by walking training after the third  
198 session. Two criteria indicated the end of walking training: 1) O<sub>2</sub> saturation < 80% or 2) 11 <

199 RPE < 13 based on the Borg's scale [28]. The maximum walking training time was determined  
200 six minutes, and individuals could have rest intervals during this period.

## 201 **Outcome measures**

202 The primary outcomes were pO<sub>2</sub> and pCO<sub>2</sub> from VBG analysis. Arterial blood gas analysis was  
203 not selected to measure the O<sub>2</sub> & CO<sub>2</sub> pressures due to two reasons; first, patients in the  
204 intermediate care have not artery line and also blood sampling by syringe is a painful procedure;  
205 second, it has been shown that VBG analysis can be considered as an acceptable alternative for  
206 arterial blood gas analysis in patients with pulmonary diseases [20]. Other primary outcome  
207 measures include Spo<sub>2</sub> after 2 minutes breathing free air, and 3MWT distance.

208 The secondary outcomes included the level of dyspnea and RPE after 3MWT using Borg's scale  
209 [15], PH of VBG, one-month and three-month related mortality rates and, HRQOL by the  
210 Persian version of SF-36 after one month and three months [29]. As recruited patients had severe  
211 disease and could not respond to SF-36 questions, we did not assess their HRQOL at the  
212 baseline.

## 213 **Statistical analysis**

214 The sample size of this study was calculated based on minimal clinically importance difference  
215 (MCID) of Spo<sub>2</sub>. Considering standard deviation (SD) of 4.4%, MCID of 4%, two steps of  
216 measurements (before and after), a correlation between measurements of .6, type I error of .05,  
217 and 80% power, a sample size of 13 participants per group was calculated. [30, 31]. As  
218 participants were patients with severe COVID-19 pneumonia and the mortality rate seems to be  
219 high in this group, 50% loss to follow-up was estimated. Finally, 40 patients were considered as  
220 a suitable sample size.

221 Stata version 13. (Stata, College, Statin, Texas) was used to analyze the data. We reported Means  
222 ± SD and frequency counts (%) for continuous and categorical data, respectively. Data normality  
223 was checked for all continuous variables using the P-P plot, Q-Q plot, and Shapiro-Wilk test.

224 Analysis of variance and covariance (ANOVA/ANCOVA) was used to determine the differences  
225 of all continuous data, with the baseline score included as a covariate (one factor, one covariate)  
226 [32, 33]. Also, we selected blood Spo<sub>2</sub> as another covariate (one factor, two covariates) due to  
227 two reasons: 1) Spo<sub>2</sub> can be considered one of the important factors to predict mortality in  
228 hospitalized patients with COVID-19 pneumonia [31, 33]. Second, the MD of Spo<sub>2</sub> between  
229 groups was more than  $.2 \times SD$  of all participants' Spo<sub>2</sub> [34]. The point estimates of effects were



230 reported as MD with a 95% confidence interval (CI), standardized mean difference (SMD) with  
231 95% CI analyzed by Cohen's d. We considered .2 - .49, .5 - .79, .8 - 1.19 and, > 1.2 valuables as  
232 small, moderate, large, and very large SMD effects, respectively. To compare three analysis  
233 models and the effectiveness of cofounder/covariable impact on the results, partial eta<sup>2</sup> effect  
234 size was provided. Change of partial eta<sup>2</sup> > 10% between three analysis models was considered  
235 important. In the analysis of categorical data, intention-to-treat (ITT) analysis was utilized for all  
236 categorical data.

237 The number needed to treat (NNT) was calculated using an online calculator for all measures  
238 [35]. This system transforms Cohen's d into NNT and therefore is difficult to interpret. Alpha ≤  
239 .05 was considered a statistically significant level.

240 The study was registered at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (ClinicalTrials.gov Identifier NCT04357340).  
241 The registration process was completed some days after recruitment and before primary  
242 completion. The reason why recruitment was not started after registration was our particular  
243 situation at that time in our center related to the pre-planned timetable for studies related to the  
244 COVID that the Research deputy of the hospital had determined. Therefore, we had to start study  
245 before having the registration number. The authors confirm that all ongoing and related trials for  
246 this drug/intervention are registered.

### 247 **Modifications to the study protocol**

248 Level of dyspnea, RPE after the 3MWT, and PH from VBG analysis were considered as  
249 secondary outcome measurements, while they were identified as primary outcomes in  
250 registration. History of intubation due to COVID-19 pneumonia was considered as another  
251 exclusion criteria. Also, the survival rate and HRQOL assessment were evaluated after three  
252 months as second follow-up. The permissions for these amendments were obtained from the  
253 ethical committee. The details and reason for the protocol modifications are presented in S1.

### 254 **Role of the funding source**

255 This study was funded by the Tehran University of Medical Sciences. The founder of the study  
256 had no role in study design, data collection, analysis, interpretation, or writing the manuscript.  
257 The corresponding author had full access to all the data in the study and is responsible for  
258 publishing the results.

## 259 **Results**

260 In April and May 2020, 255 patients were screened, of whom 40 (age:  $55.5 \pm 13.7$ ) met the  
261 criteria and were randomly allocated to PPT (n=20) or basic care (n=20) groups. From 20  
262 allocated patients to the PPT group, one (5%) was intubated at the end of the second day and  
263 died after nine days. The reason for intubation was suddenly hemodynamic instability, which  
264 was diagnosed due to pulmonary embolism. Two patients (10%) in the control group were  
265 intubated on the third day due to pneumonia progress and died three and eight days later. These  
266 participants' baseline data were included in the statistical analysis. After one and three months,  
267 four participants (10%, two in PPT and two in basic care groups) and five participants (12.5%,  
268 two in the PPT group and three in the control group) declined to participate in a telephone-based  
269 assessment of SF-36. We found all participant's living status; therefore, no sample attrition  
270 occurred. Accordingly, ITT and per-protocol were the same for categorical data analysis. The  
271 trial profile is presented in Fig 2.

### 272 **Fig 2. Trial profile.**

273 The demographic and clinical characteristics of all participants are presented in Table 1.

**Table 1. Demographics and clinical characteristics of participants.**

	PPT group (n=20)	Basic care group (n=20)
Age (y) (Mean ± SD)	54.4 ± 13.1	56.6 ± 14.4
Sex		
Male, n (%)	13 (65)	12 (60)
Female, n (%)	7 (35)	8 (40)
Height (cm) (Mean ± SD)	172.4 ± 9.3	173.4 ± 7.4
Weight (kg) (Mean ± SD)	82.6 ± 11.8	79.8 ± 19.3
BMI (kg/m <sup>2</sup> ) (Mean ± SD)	27.9 ± 4.3	26.2 ± 4.4
Comorbidity, n (%)		
Any comorbidity, n (%)	10 (50)	9 (45)
Diabetes mellitus, n (%)	5 (25)	2 (10)
Cardiovascular disease, n (%)	4 (20)	4 (20)
Pulmonary dysfunction (s), n (%)	1 (5)	1 (5)
Renal failure, n (%)	0 (0)	2 (10)
Others, n (%)	2 (10)	1 (5)
Smoker, n (%)	3 (15)	4 (20)
Occupational environmental exposure, n (%) <sup>a</sup>	2 (10)	3 (15)
Routine Ventilation Type <sup>b</sup>		
Nasal, n (%)	2 (10)	3 (15)
Face mask, n (%)	4 (20)	3 (15)
Partial rebreathing mask, n (%)	13 (65)	12 (60)
CPAP, n (%)	1 (5)	2 (10)
Duration of Stay before enrolment (Mean ± SD)	10.1 ± 11.5	9.5 ± 6.8
Baseline O <sub>2</sub> saturation (%), Mean ± SD)	83.4 ± 4.9	84.4 ± 3.9

PPT: Pulmonary physiotherapy; SD: Standard deviation; BMI: Body mass index; CPAP: Continuous positive airway pressure

<sup>a</sup> defines as patient's exposure to some materials like asbestos, arsenic, coal, etc., which can cause pulmonary disease.

<sup>b</sup> Defined as prescribed ventilation type for patient by physician which should be used most of the time.

\* All of the participant's characteristics are statistically similar between groups based on t-test and chi-square test.

276 In the crude model analysis, the mean pO<sub>2</sub> (MD: 5.81 [1.51, 10.11], SDM: .9 [.21, 1.57]), Spo<sub>2</sub>  
 277 (MD: 3.99 [1.5, 6.47], SMD: 1.07 [.37, 1.76]), 3MWT distance (MD: 81.82 [47.93, 115.7],  
 278 SMD: 1.61 [.86, 2.35]), level of dyspnea (MD: -2.08 [-2.96, -1.19], SMD: -1.57 [-2.31, -.82]),  
 279 RPE after walking (MD: -4.04 [-5.76, -2.32], SMD: -1.56 [-2.3, -.82]) and, PH (MD: .06, [.01,  
 280 .12], SMD: .74 [.71, 1.41]) were statistically significant different between groups in all analysis  
 281 models ( $P \leq .03$ , Table 2). Also, pCO<sub>2</sub> was insignificantly decreased (MD: -1.68 [-6.8, 3.44],  
 282 SMD: -.22 [-.43, .86]). In the ANCOVA with adjusting each variable to its baseline measure, the  
 283 partial eta<sup>2</sup> were improved > 10%. Considering baseline Spo<sub>2</sub>, partial eta<sup>2</sup> were slightly reduced  
 284 in all variables except level of dyspnea which was slightly increased (Table 2).

**Table 2. Distribution of different outcomes according to two arms in addition to related effect sizes.**

Clinical Outcome	PPT group (n=19)		Basic care group (n=18)		F (P value)**	MD [95 % CI]	SMD [95 % CI]	Partial eta <sup>2</sup>
	Baseline <sup>a</sup>	After <sup>a</sup>	Baseline <sup>a</sup>	After <sup>a</sup>				
pO <sub>2</sub> (mmHg)	29.4 ± 5.3	38.7 ± 5.3	30.6 ± 8.2	32.9 ± 7.5	7.5 (< .01) <sup>a</sup>	5.81 [1.51, 10.11]	.9 [.21, 1.57]	.177
					13 (< .01) <sup>b</sup>	6.43 [2.8, 10.07]	1.18 [.48, 1.88]	.276
					12.04 (< .01) <sup>c</sup>	6.39 [2.64, 10.14]	1.15 [.45, 1.84]	.267
pCO <sub>2</sub> (mmHg)	40 ± 7.3	37 ± 7.2	39.3 ± 8	38.6 ± 8.1	.44 (.51) <sup>a</sup>	-1.68 [-6.8, 3.44]	-.22 [-.43, .86]	.012
					.97 (.33) <sup>b</sup>	-2.1 [-6.36, 2.21]	-.32 [-.97, .33]	.027
					.62 (.44) <sup>c</sup>	-1.7 [-6.01, 2.65]	-.26 [-.91, .39]	.018
Spo <sub>2</sub> (Free air) (%)	83.4 ± 4.9	90.21 ± 3.4	84.4 ± 3.9	86.2 ± 4	10.63 (< .01) <sup>a</sup>	3.99 [1.5, 6.47]	1.07 [.37, 1.76]	.233
					14.2 (< .01) <sup>b</sup>	4.43 [2.04, 6.83]	1.25 [.53, 1.95]	.294
Distance of 3MWT (m)	46 ± 24.3	149.1 ± 63	50 ± 24.4	67.3 ± 33.1	24.03 (< .01) <sup>a</sup>	81.82 [47.93, 115.7]	1.61 [.86, 2.35]	.407
					67.9 (< .01) <sup>b</sup>	91.44 [68.88, 113.99]	2.72 [1.81, 3.62]	.666
					64.33 (< .01) <sup>c</sup>	91.62 [68.38, 114.86]	2.67 [1.76, 3.55]	.661
Level of Dyspnea	5 ± 2	1.54 ± 1.2	5.19 ± 1.4	3.6 ± 1.5	22.89 (< .01) <sup>a</sup>	-2.08 [-2.96, -1.19]	-1.57 [-2.31, -.82]	.395
					38.44 (< .01) <sup>b</sup>	-1.98 [-2.63, -1.33]	-2.04 [-2.83, -1.23]	.531
					36.54 (< .01) <sup>c</sup>	-1.99 [-2.66, -1.32]	-2 [-2.79, -1.2]	.525
RPE after Walking	16.2 ± 1.6	10.8 ± 3	17 ± 1.3	14.8 ± 2	22.6 (< .01) <sup>a</sup>	-4.04 [-5.76, -2.32]	-1.56 [-2.3, -.82]	.393
					18 (< .01) <sup>b</sup>	-3.46 [-5.12, -1.8]	-1.42 [-2.14, -.69]	.346
					15.67 (< .01) <sup>c</sup>	-3.32 [-5.03, -1.62]	-1.34 [-2.05, -.62]	.322
PH from VBG	7.42 ± .08	7.5 ± .07	7.44 ± .06	7.43 ± .1	5.11 (.03) <sup>a</sup>	.06 [.01, .12]	.74 [.71, 1.41]	.127
					8.38 (< .01) <sup>b</sup>	.08 [.02, .13]	.96 [.27, 1.63]	.198
					7.31 (< .01) <sup>c</sup>	.07 [.02, .13]	.9 [.22, 1.57]	.181

PPT: Pulmonary physiotherapy; pO<sub>2</sub>: Mixed venous O<sub>2</sub> pressure; pCO<sub>2</sub>: Mixed venous CO<sub>2</sub> pressure; Spo<sub>2</sub>: Oxygen saturation; 3MWT: Three-minute walk test; RPE: Rating of perceived exertion; VBG: Venous blood gas; MD: Mean difference; CI: Confidence interval; SMD: Standardized mean difference (based on Cohen's d test), ANOVA: Analysis of variance, ANCOVA: Analysis of covariance.

<sup>a</sup> Expressed as mean ± standard deviation. The baseline and after values present the result of participants' assessment before and after three days, respectively.

\*\* Analyzed using ANOVA/ANCOVA tests. F statistics and P value were reported based on Group source analysis.

<sup>a</sup> Crude analysis

<sup>b</sup> Adjusted to baseline measurement of the variable (as covariance)

<sup>c</sup> Adjusted to baseline measurement of the variable and baseline O<sub>2</sub> saturation (free air) (as covariance)

285

286 Table 3 presents all of the SF-36 domains and summary scores after one month and three  
 287 months. All scores were higher in the PPT group than the basic care group, except body pain  
 288 after one month and role limitation due to physical health, mental health, and mental component  
 289 summary score after three months. Only the differences in body pain domain score reach a  
 290 statistically significant level.

**Table3. Distribution of SF-36 domains according to two arms in addition to related effect sizes after one and three months.**

SF-36 Domain	Time	Groups		F (P-value) **	MD [95 % CI]	SMD [95 % CI]	Partial eta <sup>2</sup>
		PPT*	Basic care*				
PF	one-month <sup>a</sup>	41.7 ± 24.9	35.1 ± 23.1	.5 (.49)	6.53 [-12.44, 25.5]	.27 [-.48, 1.02]	.018
	three-month <sup>b</sup>	45.8 ± 18.6	43.3 ± 18.4	.11 (.74)	2.5 [-12.91, 17.91]	.13 [-.66, .92]	.005
RP	one-month	40.6 ± 44.6	18.7 ± 33.9	2.01 (.17)	21.87 [-9.86, 53.61]	.54 [-.23, 1.3]	.072
	three-month	54.7 ± 33.2	62.5 ± 35.8	.32 (.58)	-7.81 [-36.27, 20.65]	-.23 [-1.02, .57]	.013
BP	one-month	62.5 ± 31.4	69.4 ± 30.1	.35 (.56)	-6.94 [-31.13, 17.25]	-.22 [-.97, .53]	.013
	three-month	77.1 ± 20.1	54.4 ± 22.5	6.82 (.01)	22.64 [4.75, 40.52]	1.05 [.2, 1.89]	.221
GH	one-month	67.5 ± 28.8	60 ± 21.2	.58 (.45)	7.5 [-12.81, 27.81]	.29 [-.46, 1.04]	.021
	three-month	68.1 ± 23.2	61.5 ± 31.2	.38 (.54)	6.62 [-15.42, 28.67]	.25 [-.55, 1.04]	.016
VT	one-month	55.9 ± 32.3	55 ± 18.7	.01 (.93)	.93 [-20.57, 22.44]	.03 [-.71, .78]	.000
	three-month	58.1 ± 20.6	57.5 ± 29.8	.00 (.95)	.62 [-20.97, 19.72]	.02 [-.76, .81]	.000
SF	one-month	71.9 ± 30.4	57.3 ± 29.9	1.6 (.22)	14.59 [-9.13, 38.3]	.48 [-.28, 1.24]	.057
	three-month	76.6 ± 20.8	66.2 ± 27	1.2 (.28)	10.31 [-9.12, 29.75]	.44 [-.36, 1.24]	.046
RE	one-month	68.7 ± 41.2	58.3 ± 45.2	.4 (.53)	10.42 [-23.31, 44.14]	.24 [-.51, .99]	.015
	three-month	75 ± 39.44	73.3 ± 43.9	.01 (.92)	1.67 [-32.58, 35.91]	.04 [-.75, .83]	.000
MH	one-month	71.5 ± 26.3	68 ± 21.7	.14 (.71)	3.5 [-15.7, 22.7]	.14 [-.61, .89]	.005
	three-month	64 ± 16.2	67.6 ± 17.3	.29 (.6)	-3.6 [-17.44, 10.24]	-.22 [-1.01, .58]	.012
MCSS	one-month	51.4 ± 14.5	48.5 ± 16.3	.23 (.63)	2.82 [-14.81, 9.17]	.18 [-.57, .93]	.008
	three-month	50 ± 10.4	50.1 ± 15	.00 (.98)	-.13 [-10.41, 10.14]	.01 [-.8, .78]	.000
PCSS	one-month	37.5 ± 10.5	34.3 ± 12.2	.56 (.46)	3.24 [-5.62, 12.1]	.29 [-.47, 1.04]	.021
	three-month	42.2 ± 10.3	38.9 ± 10.3	.6 (.44)	3.21 [-5.33, 11.76]	.31 [-.48, 1.1]	.024

PF: Physical functioning; RP: Role limitations due to physical health; BP: Body pain; GH: General health; VT: Vitality; SF: Social functioning; RE: Role limitation due to emotional problems; MH: Mental health; MCSS: Mental component summary score; PCSS: Physical component summary score; PPT: Pulmonary physiotherapy; SF-36: Short form-36; Mean difference; SMD: Standardized mean difference (based on Cohen's d test); CI: Confidence interval.

\* Expressed as mean ± standard deviation.

\*\* Analyzed using ANOVA tests.

<sup>a</sup> 16 and 12 patients participated to assessment of quality of life after one month in PPT and basic care groups, respectively.

<sup>b</sup> 16 and 10 patients participated to assessment of quality of life after three months in PPT and basic care groups, respectively.

291  
 292 During one month after end of the intervention, two and six participants in the PPT group and  
 293 basic care group were died (OR=.26 [.04, 1.49], P=.13, table 4). After considering baseline Spo2  
 294 as a covariate, OR was reduced (OR=.19 [.03, 1.30], P=.09). After three months, all allocated  
 295 participants to PPT group were survived and one patient in basic care group was died (crude

296 analysis: OR=.21 [.04, 1.16], P=.073; after considering baseline Spo2 as a covariate: OR=.16  
 297 [.26, 1.05], P=.056; table 4).

**Table 4. The mortality rate of participants allocated to groups in addition to related effect sizes.**

	Allocated group	Mortality +	Mortality -	Odds ratio [95% CI]	Risk difference [95% CI]	Risk ratio [95% CI]
One-month mortality	PPT group	2 (10%)	18 (90%)	.26 [.04, 1.49]	-.2 [-.44, .04]	.33 [.08, 1.46]
	Basic care group	6 (30%)	14 (70%)			
Three-month mortality	PPT group	2 (10%)	18 (90%)	.21 [.04, 1.16]	-.25 [-.5, -.00]	.29 [.07, 1.21]
	Basic care group	7 (35%)	14 (65%)			

PPT: Pulmonary physiotherapy; CI: Confidence interval

298 No related adverse events were observed during the intervention period. The physiotherapists  
 299 reported a minimal Spo2 decrease and minimal hemodynamic instability in some patients during  
 300 PPT that was resolved a few minutes after the session. Also, the data monitoring committee  
 301 confirmed that the reason for one case intubation in the experimental group during three days  
 302 seems to not be related to the PPT.

## 303 Discussion

304 According to our knowledge, this study is the first RCT to evaluate the efficacy of the PPT  
 305 through comparison with a control group on non-intubated hospitalized patients with severe  
 306 COVID-19 pneumonia. Our designed interventions seem to be safe and effective without serious  
 307 adverse effects.

308 In general, the results show that participants' pO<sub>2</sub>, PH, 3MWT, and level of dyspnea values were  
 309 improved in the PPT group than the basic care group after adjustment of each measurement to  
 310 the baseline measure. Spo<sub>2</sub> was also higher in the PPT group than the basic care group clinically  
 311 significant after three days [30]. Based on the result of standardized mean differences, PPT  
 312 decreased pCO<sub>2</sub> with a small effect size (NNT≈ 6) and improved pO<sub>2</sub> (NNT≈ 2), venous blood  
 313 PH (NNT= 2), level of dyspnea (NNT≈ 2), and RPE after walking (NNT≈ 2) with a large effect  
 314 size, but inconclusive. PPT also improved Spo<sub>2</sub> (NNT≈ 2) and distance of 3MWT (NNT≈ 2)  
 315 with a very large effect size, but inconclusive. The NNT analyzes showed that it seems one

316 patient with severe COVID-19 pneumonia can benefit from the PPT regarding Spo2, VBG  
317 analysis, functional capacity, and dyspnea measures if it is applied to at least two patients.  
318 After one-month follow-up, PPT was associated with higher HRQOL in role limitation due to  
319 physical health domain (NNT $\approx$  3) with a moderate effect size. Also, patients in PPT group  
320 presented higher score in body pain domain of SF-36 instrument than basic care group (NNT $\approx$  2)  
321 after three months with a large effect size. Patients with COVID-19 suffer from significant  
322 physical and psychological impairments that impact their HRQOL; Therefore, interventions  
323 improving HRQOL like rehabilitation should be considered in their management [36]. Although  
324 some limited domains of SF-36 presented higher value in the PPT group than the control group  
325 at one-month and three-month with very small effect size, but higher values of other domains in  
326 the PPT group than control group can suggest that prolonged duration rehabilitation, especially  
327 after discharge, may improve physical and psychological impairments and HRQOL. It has been  
328 shown that six weeks of respiratory rehabilitation could improve respiratory function, aerobic  
329 capacity, HRQOL, and anxiety of elderly patients with COVID-19, as reported by Liu and  
330 colleagues [14].

331 Allocated participants to the PPT group had a 20% and 25% lower one-month and three-month  
332 mortality rate than the basic care group, respectively. The NNT analysis shows that PPT kept  
333 alive one out of five patients until one month. However, the results of logistic test of one-month  
334 mortality rate is not statistically significant. Based on the NNT analysis, PPT can keep alive one  
335 out of four patients until three months. A similar finding was reported in patients after lobectomy  
336 after lung cancer by Çınar et al. (2020). They showed that patient received postoperative  
337 respiratory physiotherapy had no mortality after 30 days, while patients received standard  
338 postoperative care had 8% 30-day mortality rate [37]. In a systematic review and meta-analysis,  
339 Ryrso et al. (2018) reported that supervised, early pulmonary rehabilitation could be associated  
340 to statistically significant mortality reduction (RR .58 [95% CI .34, .98]) in patients with acute  
341 exacerbation of chronic obstructive pulmonary disease compared to usual post-exacerbation care  
342 or no pulmonary rehabilitation program [38].

343 Adjusting each variable to its baseline measurement increased partial eta<sup>2</sup> > 10% than crude  
344 analysis, suggesting that even small differences of each measured outcome can change the  
345 results. A similar effect was not found about baseline Spo2.

346 There are currently some published studies with different levels of evidence, mostly review of  
347 investigations about PPT and other cases of viral pneumonia such as influenza, expert opinions,  
348 and consensus statements recommended how and when to use PPT for patients with different  
349 stages of COVID-19 pneumonia. Some researchers, physiotherapy, and rehabilitation experts  
350 have recommended PPT as an effective rehabilitative intervention for patients with all stages of  
351 COVID-19 pneumonia [4, 7, 11, 12]. Other researchers believed that only ACT should be  
352 applied in the presence of EPS to patients with the severe stage under special conditions;  
353 However, they have not suggested utilizing other PPT techniques like diaphragmatic breathing,  
354 respiratory muscle training, incentive spirometers, manual mobilization, and exercise training [1,  
355 8, 9, 13]. They explained that acute patients often have a shallow and rapid respiratory pattern  
356 that has been adapted spontaneously to make the minimal effort; therefore, any change in this  
357 strategy may harm the patient. No other reason was given for considering PPT contraindicated in  
358 the severe stage of COVID-19 pneumonia [10]. We observed some of these events like Spo<sub>2</sub>  
359 decreasing and cough stimulating, but all were resolved just some minutes after the session. In  
360 our clinical setting, we also sometimes observed that Spo<sub>2</sub> decreases during breathing through  
361 continuous positive airway pressure, while using this non-invasive ventilator is recommended  
362 [39]. Our results showed that PPT seems not to be a contraindication for severe stage COVID-  
363 19, but it also may help therapeutic procedures.

364 About 34% of patients with COVID-19 pneumonia suffer from EPS [3]; therefore, ACT can be  
365 an effective treatment for them [14]. On the other hand, the main cell target of SARS-Cov-2 is  
366 type II pneumocyte, which is responsible for pulmonary surfactant synthesis [40]. As the  
367 pulmonary surfactant increases pulmonary compliance and facilitates the recruitment of  
368 collapsed airways [41], SARS-Cov-2 may cause alveolar stiffness. As there are some time-  
369 dependent properties of the tissue like creep and stress relaxation, a possible reason for the  
370 rationality of breathing exercises in the early phase can be their roles in tissue stiffness reduction  
371 or prevent pneumonia progression. Based on this hypothesis, early PPT in the acute phase may  
372 have therapeutic, preventive, and rehabilitative roles in the management of COVID-19  
373 pneumonia. We did not have any assessment of lung tissue stiffness; therefore, our results  
374 support this possible hypothesis indirectly. Future researches with radiologic assessments that  
375 show tissue characteristics like chest computed tomography scan can test this hypothesis to some  
376 extent.



377 Our used PPT program had three main characteristics. First, choose the type of PPT technique(s)  
378 based on the patients' signs and symptoms. We used IHT with emphasis on diaphragmatic  
379 breathing and educated them on how to cough and breathe properly, but ACTs were only applied  
380 to patients with EPS signs and symptoms. Second, we also defined some criteria for holding the  
381 intervention to get better safety. Third, we set a mild aerobic exercise in addition to chest  
382 physiotherapy to prevent muscle wasting and aerobic deterioration, which are seen in patients  
383 with COVID-19 [4]. We highly recommend that patients take a sufficient dose of oxygen and be  
384 under accurate monitoring during exercises.

385 Our research had some limitations which should be considered in future studies. First, we  
386 selected the sample size as MCID of Spo2 as the primary outcome measurement, but this number  
387 seems to have not enough power for other variables. For example, allocated participants in the  
388 PPT group had a 20% lower mortality rate than the control group. This RD seems to be  
389 influential; however, the results of logistic tests in the mortality rate did not reach a statistically  
390 significant level. Therefore, further investigations with a larger sample size are highly suggested  
391 evaluating safety and efficacy of PPT in patients with COVID-19. Second, we only recruited  
392 participants from a single center. Now, different centers have particular therapeutic guidelines  
393 that can impact the results of PPT. The applied interventions in this study with three-day  
394 duration, no need for specific tools and, low risk of adverse events suggest the feasibility of  
395 multi-center investigations on PPT effectiveness and safety on hospitalized patients with  
396 COVID-19. Third, we only recruited patients with a severe stage of COVID-19. Based on the  
397 mentioned possible mechanism, PPT may be more effective if to be started before disease  
398 severity reaches to severe phase even when the symptoms appear; therefore, future researchers  
399 are recommended to investigate the efficacy of PPT in patients with mild and moderate stages of  
400 COVID-19. Fourth, as participants of this study were from different cities, we could not re-  
401 assess their respiratory functions, aerobic capacity, and level of dyspnea. It is highly  
402 recommended that future researchers follow the objective pulmonary functions up to after  
403 patients' discharge after applying PPT during the hospital stay.

## 404 **Conclusion**

405 The results of this RCT suggest early PPT during three days, including airway clearance  
406 techniques, in the presence of excessive pulmonary secretion, and inspiratory hold breathing with

407 emphasis to diaphragmatic breathing for hospitalized adult patients with a severe stage of  
408 COVID-19 pneumonia. Despite some recommendation, PPT seems to be safe and effective in  
409 the management of patients with severe COVID-19. The impact of early PPT on the mortality  
410 rate of these patients is currently indeterminate. Further researches with larger sample size are  
411 needed to evaluate the efficacy of PPT on COVID-19 patients with different severity stages.

## 412 **Contribution**

413 MJ, AS, AK, MTB, ND, and BAM made substantial contributions to the conception and  
414 designed the study. MJ, ND, and SA contributed to applying the intervention or acquisition of  
415 the data. MJ and AK analysed the data. AK was responsible for the statistical analysis. BAM was  
416 responsible for data safety monitoring during the study. MJ, ND, and BAM interpreted the data  
417 and drafted the manuscript. MJ and BAM verified the data. All authors had access to the data,  
418 revised the manuscript, and approved it.

## 419 **Declaration of interests**

420 The authors declare no competing interests.

## 421 **Data sharing**

422 All individual participant data that underline the results reported in this article, after de-  
423 identification (text, tables, figures, and appendices), statistical analysis plan and Informed  
424 consent form are available from the corresponding author and Mohammad Javaherian (Email:  
425 Javaherian\_m@razi.tums.ac.ir) for researchers who provide a related approved proposal and  
426 ethical committee approve to achieve aims. Patient-level information will be anonymised and  
427 study documents will be redacted to protect the privacy of trial patients. These data will be  
428 available with publication date until one year.

## 429 **Acknowledgment**

430 The researchers sincerely thank all physicians and nurses of intermediate care wards of IKHC.  
431 The authors would like to appreciate the methodologist's support and constructive comments (s)  
432 research development office, IKHC, Tehran, Iran.

## 433 **References**

- 434 1. Andrade AdN, Nepomuceno B, Xavier DS, Lima E, Gonzalez I, Santos JC, et al. Evidence-based  
435 Physiotherapy and Functionality in Adult and Pediatric patients with COVID-19. *J Hum Growth Dev.*  
436 2020;30(1):148-55.
- 437 2. Organization WH. Coronavirus Disease (COVID-19): Weekly Epidemiological Update (27 July  
438 2021). [https://www.who.int/publications/m/item/weekly-epidemiological-update---19-january-](https://www.who.int/publications/m/item/weekly-epidemiological-update---19-january-2021)  
439 [2021](https://www.who.int/publications/m/item/weekly-epidemiological-update---19-january-2021)
- 440 3. Organization WH. COVID-19 clinical management: living guidance, 25 January 2021. World  
441 Health Organization, 2021.
- 442 4. Wang TJ, Chau B, Lui M, Lam G-T, Lin N, Humbert S. Physical medicine and rehabilitation and  
443 pulmonary rehabilitation for COVID-19. *Am J Phys Med Rehabil.* 2020;99(9):769-74.
- 444 5. Ntoumenopoulos G, Presneill J, McElholum M, Cade J. Chest physiotherapy for the prevention of  
445 ventilator-associated pneumonia. *Intensive Care Med.* 2002;28(7):850-6.
- 446 6. Ciesla ND. Chest physical therapy for patients in the intensive care unit. *Phys. Ther.*  
447 1996;76(6):609-25.
- 448 7. Aytür YK, Köseoğlu BF, Taşkıran ÖÖ, Ordu-Gökkaya NK, Delialioğlu SÜ, Tur BS, et al. Pulmonary  
449 rehabilitation principles in SARS-COV-2 infection (COVID-19): A guideline for the acute and subacute  
450 rehabilitation. *Turk J Phys Med Rehabil.* 2020;66(2):104.
- 451 8. Vitacca M, Carone M, Clini EM, Paneroni M, Lazzeri M, Lanza A, et al. Joint statement on the role  
452 of respiratory rehabilitation in the COVID-19 crisis: The Italian position paper. *Respiration.* 2020 May 19.  
453 doi: 10.1159/000508399.
- 454 9. Thomas P, Baldwin C, Bissett B, Boden I, Gosselink R, Granger CL, et al. Physiotherapy  
455 management for COVID-19 in the acute hospital setting: clinical practice recommendations. *J*  
456 *Physiother.* 2020; 66: 73-82.
- 457 10. Lazzeri M, Lanza A, Bellini R, Bellofiore A, Cecchetto S, Colombo A, et al. Respiratory  
458 physiotherapy in patients with COVID-19 infection in acute setting: a Position Paper of the Italian  
459 Association of Respiratory Physiotherapists (ARIR). *Monaldi Arch Chest Dis.* 2020 March 25. doi:  
460 10.4081/monaldi.2020.1285
- 461 11. Liebl ME, Gutenbrunner C, Glaesener JJ. Early rehabilitation in COVID-19—best practice  
462 recommendations for the early rehabilitation of COVID-19 patients. *PHYS MED REHAB KUROR.* 2020  
463 May 5. doi: 10.1055/a-1162-4919.
- 464 12. Zeng B, Chen D, Qiu Z, Zhang M, Wang G, Wang J, et al. Expert consensus on protocol of  
465 rehabilitation for COVID-19 patients using framework and approaches of WHO International Family  
466 Classifications. *Aging Med.* 2020 July 6; doi: 10.1002/agm2.12120.
- 467 13. Yang LL, Yang T. Pulmonary rehabilitation for patients with coronavirus disease 2019 (COVID-  
468 19). *Chronic Dis Transl Med.* 2020 May 14. doi: 10.1016/j.cdtm.2020.05.002.
- 469 14. Liu K, Zhang W, Yang Y, Zhang J, Li Y, Chen Y. Respiratory rehabilitation in elderly patients with  
470 COVID-19: A randomized controlled study. *Complement Ther Clin Pract.* 2020 April 1. doi:  
471 10.1016/j.ctcp.2020.101166.
- 472 15. Nydahl P, Sricharoenchai T, Chandra S, Kundt FS, Huang M, Fischill M, et al. Safety of patient  
473 mobilization and rehabilitation in the intensive care unit. Systematic review with meta-analysis. *ATS.*  
474 2017;14(5):766-77.
- 475 16. Goñi-Viguria R, Yoldi-Arzo E, Casajús-Sola L, Aquerreta-Larraya T, Fernández-Sangil P, Guzmán-  
476 Unamuno E, et al. Respiratory physiotherapy in intensive care unit: Bibliographic review. *Enferm.*  
477 *Intensiva (English ed).* 2018;29(4):168-81.

- 478 17. Anekwe DE, Biswas S, Bussi eres A, Spahija J. Early rehabilitation reduces the likelihood of  
479 developing intensive care unit-acquired weakness: a systematic review and meta-analysis.  
480 *Physiotherapy*. 2020;107:1-10.
- 481 18. Stiller K. Physiotherapy in intensive care: an updated systematic review. *Chest*. 2013;144(3):825-  
482 47.
- 483 19. Efird J. Blocked randomization with randomly selected block sizes. *Int. J. Environ. Res. Public*  
484 *Health*. 2011;8(1):15-20.
- 485 20. Theodore AC, Manaker S, Finlay G. Venous blood gases and other alternatives to arterial blood  
486 gases. 2019; [https://www.uptodate.com/contents/venous-blood-gases-and-other-alternatives-to-](https://www.uptodate.com/contents/venous-blood-gases-and-other-alternatives-to-arterial-blood-gases)  
487 [arterial-blood-gases](https://www.uptodate.com/contents/venous-blood-gases-and-other-alternatives-to-arterial-blood-gases) (accessed January 23)..
- 488 21. Louw A, Cracco C, Cerf C, Harf A, Duvaldestin P, Lemaire F, et al. Accuracy of pulse oximetry in  
489 the intensive care unit. *Intensive Care Med*. 2001; 27: 1606-1613.
- 490 22. Yaqoob I, Quddus N, Farooq A, Zafar M, Ghaus M. Comparison of the impact of six minute walk  
491 test with three minute step test on vitals in healthy young individuals for measuring functional  
492 endurance. *RMJ*. 2019;44(3):490-3.
- 493 23. Robertson RJ, Goss FL, Metz KF. Perception of physical exertion during dynamic exercise: a  
494 tribute to Professor Gunnar AV Borg. *Percept Mot Skills*. 1998;86(1):183-91.
- 495 24. Gift AG. Validation of a vertical visual analogue scale as a measure of clinical dyspnea. *Rehabil*  
496 *Nurs*. 1989; 14: 323-325.
- 497 25. Ander DS, Aisiku IP, Ratcliff JJ, Todd KH, Gotsch K. Measuring the dyspnea of decompensated  
498 heart failure with a visual analog scale: how much improvement is meaningful? *CHF*. 2004;10(4):188-91.
- 499 26. Deputy of Treatment MoHaME. Patient Clinical Pathway COVID-19. 2020.  
500 [http://treatment.sbm.ac.ir/uploads/1-9-Patient\\_Clinical\\_Pathway\\_COVID\\_19.pdf](http://treatment.sbm.ac.ir/uploads/1-9-Patient_Clinical_Pathway_COVID_19.pdf)
- 501 27. Hillegeass E. *Essentials of Cardiopulmonary Physical Therapy: fourth edition*. Missouri: Elsevier  
502 Health Sciences, 2016.
- 503 28. Wilson RC, Jones P. A comparison of the visual analogue scale and modified Borg scale for the  
504 measurement of dyspnoea during exercise. *Clin. Sci*. 1989;76(3):277-82.
- 505 29. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The Short Form Health Survey (SF-36):  
506 translation and validation study of the Iranian version. *Qual Life Res*. 2005; 14: 875-882..
- 507 30. Tobin MJ, Laghi F, Jubran A. Why COVID-19 silent hypoxemia is baffling to physicians. *Am J*  
508 *Respir Crit Care Med*. 2020; 202: 356-360.
- 509 31. Altschul DJ, Unda SR, Benton J, de la Garza Ramos R, Cezayirli P, Mehler M, et al. A novel  
510 severity score to predict inpatient mortality in COVID-19 patients. *Sci Rep*. 2020 October 7. doi:  
511 10.1038/s41598-020-73962-9.
- 512 32. Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is  
513 statistically inefficient: a simulation study. *BMC Med Res Methodol*. 2001; 1: 1-6.
- 514 33. De Boer MR, Waterlander WE, Kuijper LD, Steenhuis IH, Twisk JW. Testing for baseline  
515 differences in randomized controlled trials: an unhealthy research behavior that is hard to eradicate. *Int*  
516 *J Behav Nutr Phys Act*. 2015 Dec 12. doi: 10.1186/s12966-015-0162-z.
- 517 34. Imbens GW, Rubin DB. *Causal inference in statistics, social, and biomedical sciences*. New York:  
518 Cambridge University Press; 2015.
- 519 35. Furukawa TA, Leucht S. How to obtain NNT from Cohen's d: comparison of two methods. *PLoS*  
520 *one*. 2011 April 27. doi: 10.1371/journal.pone.0019070.
- 521 36. Chen KY, Li T, Gong F, Zhang JS, Li XK. Predictors of health-related quality of life and influencing  
522 factors for COVID-19 patients, a follow-up at one month. *Front Psychiatry*. 2020 Nov. doi:  
523 10.3389/fpsy.2020.00668.
- 524 37.  ınar HU,  elik HK,  elik B, Dođan C. Is respiratory physiotherapy effective on pulmonary  
525 complications after lobectomy for lung cancer? *Turk Gogus Kalp Damar Cerrahisi Derg*. 2020;28(4):638.

- 526 38. Ryrso CK, Godtfredsen NS, Kofod LM, Lavesen M, Mogensen L, Tobberup R, et al. Lower  
527 mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a systematic  
528 review and meta-analysis. *BMC Pulm. Med.*. 2018;18(1):1-18.
- 529 39. Ashish A, Unsworth A, Martindale J, Sundar R, Kavuri K, Sedda L, et al. CPAP management of  
530 COVID-19 respiratory failure: a first quantitative analysis from an inpatient service evaluation. *BMJ*  
531 *Open Respir. Res.* 2020;7(1). doi: 10.1136/bmjresp-2020-000692.
- 532 40. Franks TJ, Chong PY, Chui P, Galvin JR, Lourens RM, Reid AH, et al. Lung pathology of severe  
533 acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. *Hum Pathol.* 2003; 34:  
534 743-748.
- 535 41. Desai JP, Moustarah F. Pulmonary compliance. *StatPearls [Internet]*. 2019 Feb 18.
- 536

537 **Supporting information**

538 **S1 Table. The reason for protocol modifications.**

Type of Modification	Time of modification during the study	Reason(s)
Changing the "level of dyspnea" from primary to secondary outcome measurement	Before enrollment	Their role in the sample size calculation. The role of these outcomes were not important in this research to be considered as primary outcome measurement.
Changing the "rating perceived of exertion after the three-minute walk test" from primary to secondary outcome measurement		
Changing the "Venous Blood PH" from primary to secondary outcome measurement		
Consider the history of intubation due to COVID-19 pneumonia as exclusion criteria.	Before enrollment	When the research team was preparing to start enrolling the participants, they found that there are cases weaned from mechanical ventilator recently. Based on defined inclusion/exclusion criteria, they could include in the study because they could consider patients with severe COVID-19. As the main aim of this study was to evaluate the efficacy and safety of pulmonary physiotherapy in the severe stage of COVID-19 to determine that can this treatment improve patients with COVID-19 and prevent their deterioration? Finally, the research team decided to consider the history of intubation due to COVID-19 as exclusion criteria.

539

540 The permissions of all of the modifications were taken from the ethical committee of Tehran University of Medical  
 541 Sciences.

Does patient have signs of excessive pulmonary secretion?

YES

NO

Does patient have contraindication(s) to airway clearance techniques?

NO

YES

Airway clearance techniques  
(Based on therapist's assessment and clinical decision making)

Effective cough techniques

Did the signs of excessive pulmonary secretions subside?

NO

YES

Inspiratory Hold Technique  
Diaphragmatic Controlled Breathing

### Contraindications

#### • Common:

Unstable hemodynamic status  
Pulmonary embolism  
Acute cerebrovascular diseases  
Severe hemoptysis

#### • Postural drainage:

Increased intracranial pressure  
Severe pulmonary edema  
Diaphragmatic hernia  
Recent eye surgery

#### • Percussion & Vibration:


Open wound, burns in thoracic area  
Recent skin graft  
Subcutaneous emphysema

### Patient Education:

Effective coughing  
Upper chest muscles relaxation  
Diaphragmatic Controlled Breathing  
Incentive spirometry

### Criteria for physiotherapy session hold:

- HR increased > 20 to 30 bpm above resting HR  
- HR decreased below resting HR  
- Systolic BP increased >20 to 30 mm Hg above resting level  
- Systolic BP decreased >10 mm Hg below resting level  
- Dizziness, vomiting



\* These participants were intubated during three days and therefore did not participate in the assessment after three days. They died before one-month follow-up.